EP1742534A4 - Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods - Google Patents

Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods

Info

Publication number
EP1742534A4
EP1742534A4 EP05778582A EP05778582A EP1742534A4 EP 1742534 A4 EP1742534 A4 EP 1742534A4 EP 05778582 A EP05778582 A EP 05778582A EP 05778582 A EP05778582 A EP 05778582A EP 1742534 A4 EP1742534 A4 EP 1742534A4
Authority
EP
European Patent Office
Prior art keywords
glucosamine
inflammatory
compositions
methods
mutual prodrugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05778582A
Other languages
German (de)
French (fr)
Other versions
EP1742534A2 (en
Inventor
Anthony C Capomacchia
Solomon T Garner Jr
J Warren Beach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Georgia
University of Georgia Research Foundation Inc UGARF
Original Assignee
University of Georgia
University of Georgia Research Foundation Inc UGARF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Georgia, University of Georgia Research Foundation Inc UGARF filed Critical University of Georgia
Publication of EP1742534A2 publication Critical patent/EP1742534A2/en
Publication of EP1742534A4 publication Critical patent/EP1742534A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
EP05778582A 2004-04-07 2005-04-07 Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods Withdrawn EP1742534A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56012804P 2004-04-07 2004-04-07
PCT/US2005/011739 WO2005116086A2 (en) 2004-04-07 2005-04-07 Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods

Publications (2)

Publication Number Publication Date
EP1742534A2 EP1742534A2 (en) 2007-01-17
EP1742534A4 true EP1742534A4 (en) 2011-04-13

Family

ID=35451458

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05778582A Withdrawn EP1742534A4 (en) 2004-04-07 2005-04-07 Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods

Country Status (15)

Country Link
US (1) US8361990B2 (en)
EP (1) EP1742534A4 (en)
JP (1) JP2007532562A (en)
KR (1) KR20060132036A (en)
CN (1) CN1953660A (en)
AP (1) AP2006003774A0 (en)
AU (1) AU2005248294A1 (en)
CA (1) CA2561672A1 (en)
DO (1) DOP2006000252A (en)
EA (1) EA200601648A1 (en)
EC (1) ECSP066972A (en)
IL (1) IL178500A0 (en)
MX (1) MXPA06011475A (en)
WO (1) WO2005116086A2 (en)
ZA (1) ZA200608364B (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200601648A1 (en) 2004-04-07 2007-04-27 Зе Юниверсити Оф Джорджия Рисерч Фаундейшн, Инк. GLUCOSAMINE AND GENERAL PROCEDURES GLUCOSAMINE / ANTI-INFLAMMATORY AGENT, COMPOSITIONS AND METHODS
US8034796B2 (en) 2004-04-07 2011-10-11 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
KR100780868B1 (en) * 2006-07-10 2007-11-30 부경대학교 산학협력단 Quarternized amino glucosamine compound for exerting anticancer effect
EP1902705A1 (en) * 2006-09-22 2008-03-26 Pharmatex Italia Srl Injectable pharmaceutical nimesulide solutions
KR100857509B1 (en) * 2007-01-11 2008-09-08 주식회사 티디에스팜 Transdermal preparation comprising glucosamine for treating arthritis
FR2918376B1 (en) 2007-07-04 2011-10-28 Mathieu Borge LIQUID OR PASSIZED COMPOSITIONS FOR THE CONTRIBUTION OF ESSENTIAL ELEMENTS TO THE SYNTHESIS AND CONSTITUTION OF PROTEOGLYCANS, IN PARTICULAR FOR THE TREATMENT OF CARTILAGE DEGRADATION
JP4490498B2 (en) 2008-09-30 2010-06-23 新田ゼラチン株式会社 Disease inhibitor
CN101637451B (en) * 2009-06-12 2011-03-30 陶灵刚 Lomoxicam liposome medical composition and solid formulation thereof
FR2958157B1 (en) * 2010-04-02 2012-06-29 Libragen COSMETIC AND PHARMACEUTICAL COMPOSITION COMPRISING N-ACETYL-GLUCOSAMINE-6-PHOSPHATE
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
CN104603096A (en) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
EP2847169A4 (en) 2012-05-07 2015-09-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
WO2013168003A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammation
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
JP2015518854A (en) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of multiple sclerosis
SG11201407319YA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
JP2015518855A (en) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of mucositis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
JP2015529218A (en) 2012-09-08 2015-10-05 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of inflammation and lipid disorders
RU2582278C2 (en) * 2013-04-25 2016-04-20 Закрытое Акционерное Общество "Фармфирма "Сотекс" Transdermal agent for treating and preventing joint and soft tissue diseases, method for production thereof and combined transdermal preparation for treating and preventing joint and soft tissue diseases
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
ES2898656T3 (en) * 2014-06-30 2022-03-08 Nutricos Tech Combination products and cosmetic compositions to combat skin disorders and skin aging affecting keratinocytes and/or fibroblasts and the dermis
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CN107207403A (en) 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 Composition and method for treating multiple sclerosis
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
DK3242869T3 (en) 2015-01-06 2022-01-31 Cellix Bio Private Ltd Compositions and methods for treating inflammation and pain
JP2019501221A (en) * 2015-12-30 2019-01-17 アレクサンドル・ヴィレノヴィチ・アサフォフＡＳＡＦＯＶ， Ａｌｅｘａｎｄｅｒ Ｖｉｌｅｎｏｖｉｃｈ Formulations, manufacturing methods and uses for the treatment of extracellular matrix components of peripheral joints, spinal joints and / or connective tissues
KR101785968B1 (en) * 2017-04-19 2017-10-17 주식회사 인투바이오 Cosmetic composition for improving skin condition
CN109929001B (en) 2017-12-18 2022-07-08 润佳（苏州）医药科技有限公司 Glucosamine derivative, composition thereof and medical application thereof
CN115594724A (en) 2017-12-18 2023-01-13 润佳（苏州）医药科技有限公司（Cn） Glucosamine derivatives for preventing or treating joint diseases
RU2685436C1 (en) * 2018-06-22 2019-04-18 ЗАО "ФармФирма "Сотекс" Transdermal preparation for treatment and prevention of diseases of joints and soft tissues
CN115433246A (en) * 2021-06-04 2022-12-06 润佳（苏州）医药科技有限公司 Crystal form of glucosamine derivative, preparation method and application

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1383465A (en) * 1972-05-09 1974-02-12 Sir Labo Chimico Biologi Glucosamide of 1- p-chlorobenzoyl indolyl-3-acetic acid and processes for its preparation
JPS5455545A (en) * 1977-10-12 1979-05-02 Hokuriku Pharmaceutical Glucosamide derivative
WO1999052528A1 (en) * 1998-04-11 1999-10-21 Errekappa Euroterapici S.P.A. Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application
WO2002017890A2 (en) * 2000-08-29 2002-03-07 Anastassiades Tassos P Treatment of arthritis and compositions therefore containing a n-acylated-2-glucosamine derivative
WO2002026239A1 (en) * 2000-09-26 2002-04-04 Temple University Of The Commonwealth System Of Higher Education Analgesic and glucosamine compositions
WO2004002457A2 (en) * 2002-06-27 2004-01-08 A & D Bioscience, Inc. Conjugates comprising an nsaid and a sugar and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2223051C2 (en) 1972-05-09 1983-02-03 Farmades S.p.A., Rom Monohydrate of d (+) - glucosamide of 1- (p-chlorobenzoyl) 2-methyl-5-methoxy-indolyl-3-acetic acid, process for its preparation and pharmaceutical preparation
US4278679A (en) 1980-05-01 1981-07-14 Chromalloy American Corporation Combination of two or more drugs in a single dosage form wherein one of the drugs is a physostigmine compound
US5628936A (en) 1987-03-13 1997-05-13 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
US4942038A (en) 1987-03-13 1990-07-17 Micro Vesicular Systems, Inc. Encapsulated humectant
US5000960A (en) 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4855090A (en) 1987-03-13 1989-08-08 Micro-Pak, Inc. Method of producing high aqueous volume multilamellar vesicles
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US5219538A (en) 1987-03-13 1993-06-15 Micro-Pak, Inc. Gas and oxygen carrying lipid vesicles
US5234767A (en) 1987-03-13 1993-08-10 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
US5474848A (en) 1987-03-13 1995-12-12 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5147723A (en) 1987-07-28 1992-09-15 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5032457A (en) 1988-03-03 1991-07-16 Micro Vesicular Systems, Inc. Paucilamellar lipid vesicles using charge-localized, single chain, nonphospholipid surfactants
US5104736A (en) 1988-03-03 1992-04-14 Micro-Pak, Inc. Reinforced paucilamellar lipid vesicles
AU6524990A (en) 1989-09-21 1991-04-18 Micro Vesicular Systems, Inc. Hybrid paucilamellar lipid vesicles
US5358964A (en) 1993-07-26 1994-10-25 Warner-Lambert Company Benzylidene-lactone and their thiocarbonyl analogs as inhibitors of proteoglycan degradation
WO1997015319A1 (en) 1995-10-23 1997-05-01 Queen's University At Kingston Method and pharmaceutical composition for chondrostimulation with a prostaglandin (e.g. misoprostol) and tgf-beta, optionally in combination with igf-1
US6083996A (en) 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
US6656925B2 (en) 1998-09-09 2003-12-02 Advanced Medical Instruments Composition and method of treating arthritis
US6346519B1 (en) 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
US6299902B1 (en) 1999-05-19 2001-10-09 The University Of Georgia Research Foundation, Inc. Enhanced transdermal anesthesia of local anesthetic agents
US6368618B1 (en) 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
EP2095817A1 (en) 1999-12-07 2009-09-02 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
US20040038948A1 (en) 1999-12-07 2004-02-26 Uhrich Kathryn E. Therapeutic compositions and methods
US6685928B2 (en) 1999-12-07 2004-02-03 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
US6677321B1 (en) 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
AU1953701A (en) 1999-12-09 2001-06-18 Bruce Levin Methods and compositions for treatment of inflammatory disease
WO2003099013A1 (en) * 2000-01-24 2003-12-04 Omni Nutraceuticals, Inc. Acetaminophen/non-steroidal anti-inflamatory drug-glucosamine composition
US20020022052A1 (en) 2000-04-06 2002-02-21 Dransfield Charles William Transdermal delivery system
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US6355666B1 (en) 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US20020182237A1 (en) 2001-03-22 2002-12-05 The Procter & Gamble Company Skin care compositions containing a sugar amine
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
US20050101563A1 (en) 2001-08-14 2005-05-12 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation
US20030114416A1 (en) 2001-08-14 2003-06-19 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
US20030114418A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor
US20030125303A1 (en) 2001-12-28 2003-07-03 Andrew Kucharchuk Transdermal formulation for repair and maintenance of connective tissue
US6579543B1 (en) 2002-02-22 2003-06-17 Jackie H. McClung Composition for topical application to skin
CA2484017A1 (en) 2002-04-22 2003-10-30 Pfizer Products Inc. Indol-2-ones as selective inhibitors of cyclooxygenase-2
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
JP2006516548A (en) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト Drug delivery from rapidly gelled polymer compositions
CA2417943A1 (en) 2003-01-31 2004-07-31 Tassos P. Anastassiades Weight gain and growth stimulation in mammals by n-acylated glucosamines
US8034796B2 (en) 2004-04-07 2011-10-11 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
EA200601648A1 (en) 2004-04-07 2007-04-27 Зе Юниверсити Оф Джорджия Рисерч Фаундейшн, Инк. GLUCOSAMINE AND GENERAL PROCEDURES GLUCOSAMINE / ANTI-INFLAMMATORY AGENT, COMPOSITIONS AND METHODS

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1383465A (en) * 1972-05-09 1974-02-12 Sir Labo Chimico Biologi Glucosamide of 1- p-chlorobenzoyl indolyl-3-acetic acid and processes for its preparation
JPS5455545A (en) * 1977-10-12 1979-05-02 Hokuriku Pharmaceutical Glucosamide derivative
WO1999052528A1 (en) * 1998-04-11 1999-10-21 Errekappa Euroterapici S.P.A. Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application
WO2002017890A2 (en) * 2000-08-29 2002-03-07 Anastassiades Tassos P Treatment of arthritis and compositions therefore containing a n-acylated-2-glucosamine derivative
WO2002026239A1 (en) * 2000-09-26 2002-04-04 Temple University Of The Commonwealth System Of Higher Education Analgesic and glucosamine compositions
WO2004002457A2 (en) * 2002-06-27 2004-01-08 A & D Bioscience, Inc. Conjugates comprising an nsaid and a sugar and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 197924, Derwent World Patents Index; AN 1979-44860B, XP002622645 *
GHODESWAR B C ET AL: "Synthesis and biological evaluation of glucosamine conjugate prodrug of flurbiprofen", INDIAN DRUGS, INDIAN DRUG MANUFACTURERS' ASSOCIATION, IN, vol. 40, no. 3, 1 March 2003 (2003-03-01), pages 156 - 159, XP008114056, ISSN: 0019-462X *
GHODESWAR, B. C. ET AL: "Synthesis and pharmacological evaluation of mutual prodrugs of some nonsteroidal antiinflammatory drugs with glucosamine", INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES , 66(6), 773-777 CODEN: IJSIDW; ISSN: 0250-474X, 2004, XP008133134 *
GIORDANO M ET AL: "The therapeutic activity of 1-(p-chlorobenzoyl)-5-methoxy-2-methylind ole-3-acetic acid monohydrate glucosamide in rheumatoid arthritis (double blind trial)", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, ECV EDITIO CANTOR VERLAG, AULENDORF, DE, vol. 25, no. 3, 1 March 1975 (1975-03-01), pages 435 - 437, XP008133183, ISSN: 0004-4172 *
HANESSIAN S ET AL: "One-step stereocontrolled synthesis of [alpha]-anomeric carboxylic acid esters from unprotected glycosyl donors: A water-soluble aspirin pro-drug analogue", SYNTHESIS, GEORG THIEME VERLAG, STUTTGART, DE, no. 14, 1 January 2002 (2002-01-01), pages 1959 - 1968, XP002527135, ISSN: 0039-7881, DOI: 10.1055/S-2002-34372 *

Also Published As

Publication number Publication date
WO2005116086A2 (en) 2005-12-08
US8361990B2 (en) 2013-01-29
CA2561672A1 (en) 2005-12-08
US20120021046A1 (en) 2012-01-26
JP2007532562A (en) 2007-11-15
AP2006003774A0 (en) 2006-10-31
KR20060132036A (en) 2006-12-20
DOP2006000252A (en) 2007-09-30
IL178500A0 (en) 2007-02-11
CN1953660A (en) 2007-04-25
AU2005248294A1 (en) 2005-12-08
ECSP066972A (en) 2007-03-29
MXPA06011475A (en) 2007-04-25
WO2005116086A3 (en) 2006-08-24
EA200601648A1 (en) 2007-04-27
ZA200608364B (en) 2008-06-25
EP1742534A2 (en) 2007-01-17

Similar Documents

Publication Publication Date Title
IL178500A0 (en) Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
GB0424891D0 (en) Topical compositions
IL179438A0 (en) Levodopa prodrugs, and compositions and uses thereof
EP1895838A4 (en) Compositions and methods
EP1954708A4 (en) Methods and compositions involving intrinsic genes
EP1718714A4 (en) Tracer-containing compositions
EP1720957A4 (en) Fertilizer compositions
GB0601143D0 (en) Uses, methods and compositions
ZA200904425B (en) Nemathical compositions
GB0518769D0 (en) Topical formulations
GB0507208D0 (en) Anti-inflammatory formulation
EP1962852A4 (en) Compounds, compositions and methods
PL1888024T3 (en) Topical compositions
TWI347757B (en) Upstream power cutback
EP1859834A4 (en) Anti-inflammatory agent
GB0405406D0 (en) Anti-vaginitis compositions
EP2088865A4 (en) Guggulphospholipid methods and compositions
ZA200701197B (en) Compositions
GB0501348D0 (en) Compositions and methods
EP1865777A4 (en) Stannsoporfin compositions and administration
GB0410140D0 (en) Compositions
EP1895843A4 (en) Micogel topical formulations
GB0420627D0 (en) Monoglyceride-containing compositions
GB0516558D0 (en) Topical compositions
GB0424497D0 (en) Anti-inflammatory agent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061102

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

A4 Supplementary search report drawn up and despatched

Effective date: 20110315

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20110504